Why did Resonance Health (ASX:RHT) upgrade its FY26 profit guidance?

Resonance Health upgraded its underlying EBITDA guidance to $2.6 million, a 30% increase from the previous $2.0 million estimate. The upgrade is driven by strong operational performance, improved cost efficiencies, and a strategic shift toward higher-margin activities like Software-as-a-Medical-Device.

Why is Resonance Health's revenue guidance lower if profit is going up?

The company revised its FY26 revenue guidance down slightly to $16.0 million from $17.0 million due to the timing of revenue recognition for a major $13.8 million clinical trial agreement.

What does the "margin expansion" mentioned by Resonance Health (ASX:RHT) actually mean?

Resonance Health expects its underlying EBITDA margin to hit 16.3% in FY26, up from the previously forecasted 11.8%. This expansion indicates that the company's core services, particularly in clinical trials and SaMD, are generating more profit per dollar of sales.

Is the profit boost for Resonance Health (ASX:RHT) sustainable or a one-off event?

Management states the upgraded guidance is driven by recurring operational improvements and higher-margin services rather than one-off accounting items. By focusing on Software-as-a-Medical-Device (SaMD) and clinical trial services, the company is attempting to build a more scalable and predictable earnings base.

What are the long-term financial targets for Resonance Health?

The company is working toward a medium-term goal of reaching $30 million in annual revenue with an underlying EBITDA margin of 25%. Achieving these targets would represent a significant scale-up from the current FY26 guidance of $16 million in revenue and a 16.3% margin.

What are the main "bull" points for Resonance Health (ASX:RHT) shareholders?

The primary bullish signal is the 30% jump in profit guidance despite lower short-term revenue, showcasing strong profitability and cost management. Additionally, the company has secured a major $13.8 million contract, providing clear revenue visibility through FY27.

Resonance Health upgrades FY26 profit guidance

Written by Isaac FrancisPublished May. 5 2026Last Updated May. 5 2026

Perth-based medical technology firm Resonance Health (ASX:RHT) announced an upgrade to its financial guidance for the year ending June 30, driven by robust operational performance and an aggressive expansion into high-margin sectors.

The company now forecasts an underlying EBITDA of approximately $2.6 million, representing a substantial 30% increase over previous estimates of $2 million.

The profitability boost comes despite a slight downward revision in annual revenue projections to $16 million, a shift attributed primarily to the timing of revenue recognition for a major $13.8 million clinical trial agreement, with a larger portion of that contract now expected to materialise in FY27.

The upgrade highlights Resonance’s evolving business model, which increasingly prioritises Software-as-a-Medical-Device and clinical trial services.

The higher-margin activities have propelled the company's expected underlying EBITDA margin to 16.3%, well ahead of earlier forecasts.

Management maintains that this margin expansion is underpinned by disciplined cost control and improved operating leverage rather than one-off items.

The result serves as a critical milestone in the company’s medium-term strategy to scale annual revenue towards $30 million while targeting an underlying EBITDA margin of 25%.

At the time of reporting, Resonance Health's share price was $0.050.